Syros to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in fireside chats at two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference will take place on November 23, 2021, with a pre-recorded chat available on-demand at 10:00 a.m. ET. The JMP Securities Hematology and Oncology Summit is scheduled for December 6, 2021, at 10:40 a.m. ET. Webcasts and archived recordings can be accessed on Syros' website. The company is focused on developing gene expression medicines and has a robust clinical pipeline.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in fireside chats at two upcoming virtual investor conferences. Management will also be available for one-on-one meetings.

Piper Sandler 33rd Annual Healthcare Conference
Date: Tuesday, November 23, 2021
Presentation Time: A pre-recorded fireside chat will be made available on-demand beginning at 10:00 a.m. ET

JMP Securities Hematology and Oncology Summit
Date: Monday, December 6, 2021
Presentation Time: 10:40 a.m. ET

To access the webcasts and subsequent archived recording of each fireside chat, please visit the Investors & Media section of the Syros website at www.syros.com. An archived replay of each webcast will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: tamibarotene, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors and blood cancers. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005077/en/

Media Contact:

Courtney Solberg

Syros Pharmaceuticals

917-698-9253

csolberg@syros.com

Investor Contact:

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

What events will Syros Pharmaceuticals participate in November and December 2021?

Syros Pharmaceuticals will participate in the Piper Sandler 33rd Annual Healthcare Conference on November 23, 2021, and the JMP Securities Hematology and Oncology Summit on December 6, 2021.

What is the date and time of the fireside chat at the Piper Sandler Conference?

The fireside chat at the Piper Sandler 33rd Annual Healthcare Conference will be available on-demand starting at 10:00 a.m. ET on November 23, 2021.

When will the JMP Securities Hematology and Oncology Summit be held?

The JMP Securities Hematology and Oncology Summit will be held on December 6, 2021, at 10:40 a.m. ET.

How can I access the webcasts from Syros Pharmaceuticals' investor conferences?

Webcasts and archived recordings of the fireside chats can be accessed on Syros Pharmaceuticals' website in the Investors & Media section.

What is the focus of Syros Pharmaceuticals' drug development?

Syros Pharmaceuticals focuses on controlling gene expression and has a clinical-stage pipeline targeting diseases like myelodysplastic syndrome and acute myeloid leukemia.